473416-91-0

Basic information

• Product Name: BENZALDEHYDE, 5-BROMO-2,4-DIFLUORO
• Synonyms: BENZALDEHYDE, 5-BROMO-2,4-DIFLUORO;5-BroMo-2,4-difluorobenzaldehyde
• CAS NO: 473416-91-0
• Molecular Formula: C₇H₃BrF₂O
• Molecular Weight: 221
• Mol File: 473416-91-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 229.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.758±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: BENZALDEHYDE, 5-BROMO-2,4-DIFLUORO(CAS DataBase Reference)
• NIST Chemistry Reference: BENZALDEHYDE, 5-BROMO-2,4-DIFLUORO(473416-91-0)
• EPA Substance Registry System: BENZALDEHYDE, 5-BROMO-2,4-DIFLUORO(473416-91-0)

Safety Data

• Hazardous Substances Data: 473416-91-0(Hazardous Substances Data)

Usage

General Description

Benzaldehyde, 5-bromo-2,4-difluoro, is a chemical compound used mainly for industrial applications, particularly in organic synthesis. Its molecular formula is C7H3BrF2O and it is classified under aromatic halides and aromatic fluorides. The key elements that make up this compound are carbon, hydrogen, bromine, and fluorine. It is a derivative of benzaldehyde, which is a simple aromatic aldehyde. This chemical is characterized by its strong aromatic scent and can be hazardous upon skin or eye contact, ingestion, or inhalation. For this reason, safety precautions should be taken while handling and storing this chemical. Its properties may vary, including its physical state, color, and solubility, depending on factors such as temperature and pressure.

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 28342-75-8 1,5-dibromo-2,4-difluorobenzene 
• 348-57-2 2,4-difluorobromobenzene 

Downstream Products

• 1585970-78-0 (R)-N-((S)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(3,5-dimethylisoxazol-4-yl)-4-oxobutan-2-yl)-2-methylpropane-2-sulfinamide 
• 1585971-39-6 (R,E)-N-(1-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)ethylidene)-2-methylpropane-2-sulfinamide 
• 1616105-35-1 1-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)ethanone 
• 1616100-67-4 1-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)ethanol 
• 1616100-26-5 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(2,4-dimethylisoxazol-5-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616100-25-4 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(2,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616101-01-9 (4S,6R)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(2,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616100-22-1 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616100-10-7 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(3,5-dimethylisoxazol-4-yl)-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616099-61-6 (4S,6S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-6-(3,4-dimethoxyphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine 
• 1616100-78-7 N-(((2S,4R)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(2,4-dimethyloxazol-5-yl)-4-hydroxybutan-2-yl)carbamothioyl)benzamide 
• 1616100-77-6 (1R,3S)-3-amino-3-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-1-(2,4-dimethyloxazol-5-yl)butan-1-ol 
• 1616100-76-5 (R)-N-((2S,4R)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(2,4-dimethyloxazol-5-yl)-4-hydroxybutan-2-yl)-2-methylpropane-2-sulfinamide 
• 1616100-75-4 (R)-N-((S)-2-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-(2,4-dimethyloxazol-5-yl)-4-oxobutan-2-yl)-2-methylpropane-2-sulfinamide 

Relevant articles and documents

4-(3-AMINO-6-FLUORO-1H-INDAZOL-5-YL)-1,2,6-TRIMETHYL-1,4-DIHYDROPYRIDINE-3,5-DIC ARBONITRILE COMPOUNDS FOR TREATING HYPERPROLIFERATIVE DISORDERS

The present invention covers 4-(3-amino-6-fluoro-1H-indazol-5-yl)-1,2,6-trimethyl-1,4- dihydropyridine-3,5-dicarbonitrile compounds of general formula (I) : in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases.

4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or -CH3; or R1 and R2 can join together in a ring by adding -(CH2)4-; R3 is hydrogen or C1-C3 al-kyl; Y and Z are independently a C6-C10- aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, halo C1-4 alkyl, CN, C1-C6, alkyl or cycloalkyl, C1-C6 alkoxy, -C=OC1-4 alkyl, -SO2C1-4 alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, ben-zyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is -NHCO-, or is a single bond; and L and Z to-gether can be absent

17α-HYDROXYLASE/C17,20-LYASE INHIBITORS

The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.